Boston's Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center are globally renowned prostate cancer programmes managing complex mCRPC and hormone-sensitive metastatic prostate cancer cases. For Boston patients facing coverage gaps, high co-payments, or self-funding treatment, Abiranamo 250mg delivers the same life-extending Abiraterone Acetate as brand Zytiga at up to 95% lower cost without compromising the clinical outcomes Boston's oncologists expect.
Boston's research-active oncology environment means patients are often deeply informed about generic equivalence and quality standards. WHO-GMP certified Abiranamo from Unnati Pharmax meets this informed community's expectations. Visit unnatipharmax.com |
+91 82650 41513
FAQ 1: Why must Abiranamo be taken with prednisone/prednisolone and what happens if steroid is omitted?
Boston's research-active oncology environment means patients are often deeply informed about generic equivalence and quality standards. WHO-GMP certified Abiranamo from Unnati Pharmax meets this informed community's expectations. Visit unnatipharmax.com |
+91 82650 41513FAQ 1: Why must Abiranamo be taken with prednisone/prednisolone and what happens if steroid is omitted?
Abiraterone (Abiranamo) blocks CYP17A1, an enzyme critical not just for androgen synthesis in the testes and adrenal glands but also for cortisol production. By suppressing CYP17A1, Abiraterone causes compensatory rises in ACTH (adrenocorticotrophic hormone) that drive overproduction of mineralocorticoids — particularly aldosterone and its precursors — upstream of the block. These excess mineralocorticoids cause hypertension, hypokalemia (low potassium), and fluid retention. Low-dose prednisone (5-10mg daily) suppresses ACTH, preventing mineralocorticoid excess and these side effects, while also providing physiological cortisol replacement for the adrenal suppression Abiraterone causes. Omitting prednisone leads to mineralocorticoid excess syndrome — uncontrolled blood pressure, severe potassium depletion, and dangerous fluid retention — making co-administration non-negotiable.
